1 **Title**: Efficiency and efficacy of sensing-monopolar recordings from the subthalamic nucleus in
2 Parkinson's disease at initial programming: a comparison to traditional methodology
3
4

5 **Authors:** John A. Thompson, PhD[1,2,3*], Erin M. Radcliffe, BS[1,4*], Steven Ojemann, MD[1,2], Daniel R.
6 Kramer, MD[1], Pamela David-Gerecht, PhD[1], Michelle Case, PhD[5], Caleb Zarns, BS[5], Abbey Holt-
7 Becker, PhD[5], Robert S. Raike, PhD[5], Alexander J. Baumgartner, MD[1,2], Drew S. Kern, MD[1,2]
8
Authors:
[1]University of Colorado Anschutz Medical Campus, Department of Neurosurgery
[2]University of Colorado Anschutz Medical Campus, Department of Neurology
[3]University of Colorado Anschutz Medical Campus, Department of Psychiatry
[4]University of Colorado Anschutz Medical Campus, Department of Bioengineering
[5]Medtronic, Inc., Neuromodulation
*Co-first authors made equal contributions to the work

16
17 **Running title**: DBS monopolar sensing for programming
18
19
20 Total Word Count: 3670
21 Abstract Word: 249
22 Movement Disorders
23 Type: Original Research
24

Corresponding Author:
John A. Thompson PhD
Associate Professor
Departments of Neurosurgery, Psychiatry and Neurology
University of Colorado Anschutz Medical Campus
Research Complex II, Rm 5119
12700 E 19th Ave, Aurora, Co 80045 | Mail Stop 8601
E: john.a.thompson@cuanschutz.edu
P: 303.724.8581

34
35

Abstract

Background: Optimizing deep brain stimulation (DBS) in Parkinson's disease (PD) requires a complex process for evaluating clinical benefit and adverse effects. Localizing the contact with maximum beta (13-30Hz) power using a novel in-clinic sensing-monopolar (SenseMP) recording may improve the efficiency of selecting clinically optimal DBS settings.

Objective: Compare the clinical outcomes of optimal programming settings determined by SenseMP versus standard-of-care monopolar review (ReviewMP) for DBS therapy in PD.

Methods: Ten PD patients (4F/6M, post-diagnosis = 9.2 ± 3.5 years; on/off percent change = 43.7 ± 14.0) with bilateral subthalamic nucleus (STN) DBS were recruited. Independent evaluation of unilateral STN DBS was assessed with both SenseMP to identify the DBS contact detecting maximum beta peak power and ReviewMP. MDS-UPDRS Part III assessments for unilateral symptoms were compared between SenseMP and ReviewMP, and the time to complete these two conditions was recorded.

Results: Change from baseline in overall clinical outcomes did not differ between conditions (SenseMP = 60.5%, ReviewMP = 60.1% (p = 0.85); 19 hemispheres), nor were there differences in sub-analysis for bradykinesia, rigidity, and tremor. Using SenseMP to identify and conduct single contact ReivewMP was more time efficient than ReviewMP: 17.1 ± 4.2 minutes vs. 129.9 ± 24.9 minutes (p = 3.6e-15). SenseMP identified the maximum beta contact in SenseBP pairs at a specific level (17/20 times).

Conclusion: This study demonstrates that SenseMP localization of maximum beta peak power for DBS contact selection provides equivalent clinical efficacy to ReviewMP at a fraction of the required time.

Introduction

Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) is a neurosurgical treatment option for Parkinson's Disease (PD) complicated by motor fluctuations, bothersome dyskinesias, and/or pharmacological-resistant tremor[1-5]. Optimal DBS targeting and subsequent programming within the sensorimotor region of the STN effectively attenuates cardinal PD motor symptoms and enables reduced medication dosages[6-10]. Although recent advances in DBS electrode design have enabled independent contact control and directional field steering, the increased complexity and flexibility of these designs create multiple degrees of freedom, decreasing the efficiency of standard programming protocols[11-16]. Given the increased time demands and challenges presented by this expanding parameter space, efficient and objective strategies for DBS contact selection and programming, guided by neuroimaging, kinematic assessments, computational tools, and electrophysiological biomarkers, are under development and aimed toward delivering patient-centered therapy within a feasible clinical workflow. Several studies support the use of LFP features, specifically within the beta range (13-30 Hz), as potential biomarkers for guiding DBS programming in PD, but lack an intuitive process to select final stimulation contact due to sensing configurations available on implanted devices today[17,18].

Current clinical-commercial tools permit spectral analysis of LFP features present in power spectral densities (PSDs). However, systematic strategies for quantifying and interpreting this data have not been standardized[19-21]. Available implementations use bipolar sensing (SenseBP) montages to determine the optimal DBS contact through meticulous comparison of maximal beta peak amplitudes present in LFP PSDs[19-21]. However, determining the largest peak amplitude differential between contact pairs is reliant on trial and error and requires expertise in interpreting computed measurements[12,18,19]. Furthermore, SenseBP configurations do not clarify which contact within or between a selected contact pair detects the maximal beta peak, complicating clinical interpretability.

In this study, we utilized an investigational Percept™ SP Advanced Sense research system to

enable a monopolar sensing (SenseMP) configuration for collecting LFP data. The contact

segment that detected the greatest beta peak power based on SenseMP was then clinically

programmed. Assessments of beta power measurements for each possible contact

configuration (segment and level) were determined for SenseMP and for SenseBP pairs.

Thereafter, standard-of-care monopolar review (ReviewMP) was performed. We then

compared the time required and clinical outcomes of SenseMP versus ReviewMP.

Figure 1: Workflow diagram of the study design

Methods

Subject Information

Our study was carried out in accordance with the Colorado Multiple Institution Review Board

(COMIRB # 21-4938) and the Declaration of Helsinki, with written informed consent obtained

from all study participants. Patients were recruited from the University of Colorado Anschutz

Medical Campus, Advanced Therapies in Movement Disorders program. All PD subjects

Subject	Sex (F/M)	Age [1]	Disease Duration[1]	LEDD	MDS-UPDRS-III OFF/ON*	Duration[2]: Surgery to SV1	Duration[2]: SV1 to SV2
1	F	60's	8	715	30/15	42	2
2	F	50's	11	1860	44/21	28	1
3	F	50's	8	1097	47/33	41	1
4	M	60's	8	1198	31/9	34	1
5	M	60's	13	1460	47/39	20	1
6	M	60's	12	1454	48/24	25	7
7	M	40's	16	1863	49/30	34	1
8	F	70's	4	854	57/28	27	5
9	M	60's	6	1053	28/16	22	1
10	M	60's	6	969	49/32	40	3
MEAN	4/6	61.4	9.20	1252	43/24.7	31.30	2.3
STD	-	6.69	3.71	397.2	9.8/9.4	8.04	2.11

F: female, M: male, 1: in years, LEDD: levodopa equivalent daily dose, * pre-operative "ON" as being on medication and "OFF" as after at least 12 hours of withholding from medication, 2: in days, SV1: study visit 1, SV2 study visit 2, STD: standard deviation.

underwent a standardized evaluation process for DBS candidacy and had at least a score of 2 or

greater for any item assessing upper limb bradykinesia (items 3.4, 3.5, 3.6, 3.7, 3.8) and rigidity

(item 3.3) of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-

UPDRS) Part III in the off-medication state [22]. Subsequently, subjects were implanted bilaterally

into the STN with the Medtronic SenSight™ B33005 directional DBS leads connected to the

Percept™ PC implantable neurostimulator with BrainSense™. The B33005 DBS lead consists of

four levels (termed 0, 1, 2, and 3) with 0.5mm vertical spacing, and the middle two levels are

segmented into thirds (1a, 1b, 1c and 2a, 2b, 2c). A contact ring (i.e., 0, 3 or summation of a

middle contact arrangement (e.g., 1a, 1b, and 1c)) is termed "level," and an independent

contact (e.g., 1a) is termed "segment". The surgical procedure has been previously described[23].

Study Workflow

For each session, subjects withheld dopaminergic medication for at least 12 hours prior to the

study visit. The following workflow was used for each session and is similar in design to

previous work (Figure 1)[19]. In the -medication/OFF-stimulation condition (baseline) with the

subject seated, eyes open and resting, a SenseMP recording was conducted for all levels (N=4)

and segments (N=6) of the DBS lead. The investigational-use Percept™ SP Advanced Sense

research system was used to collect LFP data to enable the SenseMP configuration. This

investigational system enabled collection of LFP data using the novel monopolar sensing

configuration, the Percept™ SP Advanced Sense research system takes measurements between

the electrode being sensed on the implanted DBS lead to a common reference electrode on the

other implanted DBS lead. This enables isolation of activity from a single contact or set of

contacts for SenseMP recordings. The implanted neurostimulator maintained standard

commercial operation, and stimulation was turned off and not affected while using the

research system. LFP data were collected from one hemisphere per session. A sensing montage

that iterated through 5 predetermined configurations (SenseMP Segment, SenseMP Level,

SenseBP Segment Set 1, SenseBP Segment Set 2, SenseBP Level) was performed to wirelessly

stream LFP data at 250Hz for 55 seconds per recording. All recordings passed through two low-

pass filters set to 100 Hz and two high-pass filters set to 1 Hz (for both bipolar and monopolar

contact configurations). We collected all possible monopolar configuration recordings (levels =

4, segments = 6, total configurations = 10) and all possible bipolar configurations (n = 15;

bipolar configurations are available on commercial systems). Three trials of each montage were

collected to account for variability. The contact level and segment identity, maximum beta peak

amplitude, and the frequency of the maximum beta peak were noted for each hemisphere. The

contact with the maximum beta peak determined by SenseMP was used for comparison to the

contact(s) identified by standard of care monopolar review (ReviewMP).

Subsequently, a traditional ReviewMP of all DBS levels (n=4) and segments (n=6) was

performed by a movement disorders neurologist (examiner) blinded to the outcomes of the

montage recordings[19]. Briefly, pulse width (60 μs) and frequency (125Hz) were maintained

while amplitude was increased by 0.2 mA increments up to 5mA or until stimulation-induced

adverse effects were observed. All side effects were recorded, including transient (those that

resolved within 1 min) and persistent (those that lasted >1 min or included muscle

contractions). Clinical benefit was determined by improvement in wrist and elbow rigidity.

Upon completion, the clinician selected the contact(s), either the level or segment, that

predominately had the greatest therapeutic window (TW), defined as the difference in DBS

amplitude thresholds for initial clinical benefit and stimulation-induced adverse effects.

The total duration required to complete sensing (SenseMP and SenseBP) and ReviewMP were

determined as follows: Recording of time was initiated for sensing once the research telemetry

communicator was positioned over the neurostimulator and stopped upon verification of

collection of all data at the conclusion of the third sensing research recording. For ReviewMP,

recording of time was initiated upon placement of the clinical telemetry communicator and

stopped at the end of testing the final contact. To determine the estimated time required to

conduct the ReviewMP of the SenseMP identified contact, we used the following calculation.

We estimated the total time per individual ReviewMP test (i.e., 0.2mA for 1ABC), by dividing

the total time required for ReviewMP by the number of individual amplitude tests. Then, with

the identified SenseMP contact, we computed the total duration for ReviewMP of that contact

(i.e., all amplitude tests for 1A), by multiplying the individual ReviewMP test time by the

number of amplitude tests for the identified contact. To this ReviewMP duration, we added the

time required to evaluate SenseMP Level and SenseMP Segment (55 seconds x2). This value

was compared to the total ReviewMP duration (Figure 2A).

Clinical outcomes were compared between SenseMP and ReviewMP contact configurations

based on random condition presentation and double blinding of the examiner and subject.

Furthermore, the examiner was not present during the acclimation of each condition to

minimize unblinding. The DBS amplitude for each condition was set at -0.2mA from the

stimulation-induced adverse effect or up to 4.8mA based on ReviewMP assessment. Following

a ~2-minute wash-in phase, the examiner performed a unilateral MDS-UPDRS of the following

items: wrist, elbow, ankle, and knee rigidity (item 3.3), bradykinesia (items 3.4, 3.5, 3.6, 3.7,

3.8), and tremor (items 3.15, 3.16, 3.17, and 3.18). Between conditions, stimulation was turned

off, and the subject was assessed until a return to clinical baseline in the OFF-medication/OFF-

stimulation state was confirmed by the examiner. Upon return to baseline, the examiner left

the room to allow for acclimation to the second condition, and then the steps described above

were then repeated. If the SenseMP and ReviewMP resulted in identical contact selection, then

only one clinical assessment was performed, and the examiner was not notified until exiting the

room. At the conclusion of both assessments, the blinded clinician selected the optimal

configuration based upon clinical examination. To quantify the percent difference between

each condition and the baseline OFF-medication / OFF-stimulation state at the beginning of the

session, the following equation was used: (ABS(OFF-stimulation – ON-stimulation)/OFF-

stimulation)*100. For the final clinical comparison, 19 out of 20 hemispheres were evaluated.

For one hemisphere (4L), annotation error led to the incorrect selection of the contact with the

maximum beta power for MDS-UPDRS comparison.

Assessment of segment orientation

Medtronic SureTune™ 4 imaging software was used to perform DBS lead orientation analysis.

Each subject had pre-operative anatomical imaging, including MRI T1 and T2 weighted, and a

post-operative CT scan performed within 24 hours post-implant, as part of standard-of-care for

DBS surgery. All images were imported into SureTune™ 4, and pre-operative MRI and post-

operative CT images were fused to identify the anatomical location of the DBS lead. The

Medtronic SenSight™ DBS lead has unique orientation markers that allow for automatic

orientation of the lead enabled by SureTune™ 4 software. The anatomical direction for each

segmented electrode was viewed from an axial slice and was recorded. The anatomical

directions included lateral, medial, anterior, and posterior.

Statistical Analysis

All statistical tests were conducted using MATLAB (v2024a). Mean differences in duration

between SenseMP and ReviewMP were tested using a two-sided paired t-test (alpha = 0.05).

Mean differences between MDS-UPDRS Part III total sub-scores were tested with an ANOVA,

and individual sub-scores for rigidity, bradykinesia, and tremor were compared between

conditions using Tukey's HSD post-hoc pairwise comparisons. Level representation and

segmented contact orientation differences between SenseMP and

ReviewMP were compared using a Chi-Square test for independence. Within-subject

hemispheric differences between SenseMP-determined maximum beta peak amplitudes and

frequencies were compared with a two-sided paired t-test. All count comparisons for SenseMP-

segment, SenseMP-level, SenseBP-segment, and SenseBP-level were conducted using Chi-

square goodness of fit assuming equal distributions as the null hypothesis.

<u>Results</u>

Demographics

Ten PD subjects (females = 4 / males = 6; 69.0 ± 4.5 years old at time of study; disease age of

onset: 61.4 ± 6.7; PD duration in years: 9.2 ± 3.5; mean ± standard deviation – throughout the

text, '±' will refer to the same descriptive statistics) participated in the study. Table 1

provides the demographics of the subjects. Sessions were conducted following lead

implantation surgery 18.2 ± 7.3 days post-implantable neurostimulator implant and 27.2 ± 6.3

days post-lead implant. Across subjects, sessions were separated by an average of 2.5 ± 2.5

days. Analysis was performed for both right and left hemispheres per subject for a total of 20

hemispheres.

Within-subject comparisons of SenseMP beta parameters

We previously described the variability of beta peak frequency and amplitude using the same

platform, excluding SenseMP[18]. Therefore, in the current study, we focused on SenseMP to

evaluate within-subject differences across trials. There was no difference in within-subject beta

peak frequency, amplitude, or contact determined by maximum beta power across three trials

(peak: $F(2,57) = 0.155$, $p = 0.85$; amplitude: $F(2,57) = 0.016$, $p = 0.98$; contact: $F(2,57) = 0.063$, p

$= 0.93$). Analysis was therefore performed on resulting PSDs resulting from the average across

the three recording samples.

Table 2 denotes subject and hemisphere-based observations of the beta peak frequency and

power identified by SenseMP and the corresponding beta peak power of ReviewMP. No

differences were observed between left and right hemispheres for the peak frequency at which

the maximum beta power was derived (right Hz = 16.2 ± 2.22, left Hz = 16.9 ± 2.59; $t(9) = 1.07$, p

$= 0.3$), or for the amplitude of the maximum beta microvolt peak (right μVp = 3.15 ± 2.46, left

μVp = 3.09 ± 1.68); $t(9) = -0.101$, $p = 0.92$). The contact with the second-greatest beta peak was

on the same level as the contact with the greatest beta peak in 17/20 cases. As an example, if

1c had the highest beta peak power measured on the segments, then the 1a or 1b segment had

the second-highest beta peak. In 17/20 hemispheres, the SenseMP defined segment was on the

level of the maximum beta peak. In the three hemispheres that differed, the level of the

maximum beta peak was on the most ventral (2) or dorsal contact (1), which are not

segmented. In these three cases, the SenseMP level with the second highest beta peak power

was a segmented level and corresponded with the SenseMP segmented contact. In 19/20

hemispheres, SenseMP resulted in a segment contact. In all 19 cases that resulted in a segment

contact, the SenseMP segment corresponded with the SenseMP level of segments (1abc or

2abc) that had the greatest beta power peak of only the segmented levels.

Subject	Hemisphere	Peak Freq (Hz)	Configuration	Contact	Peak Amp (μVp)	TW (mA)
1	Left	15.6	SenseMP	2a	6.1	3.6
			ReviewMP	2b	2.5	4.6
			Level	2abc	3.7	1.6
	Right	14.6	SenseMP	2b	4.1	4.4
			ReviewMP	2b	4.1	4.4
			Level	2abc	3.1	2.6
2	Left	21.5	SenseMP	2b	3.0	4.6
			ReviewMP	2abc	2.7	3.6
	Right	16.6	SenseMP	2b	2.7	4.2
			ReviewMP	2b	2.7	4.2
			Level	2abc	1.8	1.4
3	Left	13.7	SenseMP	1b	4.1	4.6
			ReviewMP	1b	4.1	4.6
			Level	1abc	4.1	3.4
	Right	13.7	SenseMP	1a	3.4	2.4
			ReviewMP	2b	1.6	4.4
			SMP Level	1abc	2.6	3.2
			RMP Level	2abc	1.9	3.2
4	Left	16.6	SenseMP	3	5.6	2.6
			ReviewMP	2a	3.6	4.2
			RMP Level	2abc	3.0	2.4
	Right	17.6	SenseMP	1b	8.9	3.4
			ReviewMP	1b	8.9	3.4
			Level	1abc	7.7	1.4
5	Left	16.6	SenseMP	1a	2.1	2.4
			ReviewMP	1abc	1.2	2.6
	Right	15.6	SenseMP	1a	1.4	1.8
			ReviewMP	1abc	1.1	2.0
6	Left	17.6	SenseMP	1c	0.9	3.6
			ReviewMP	2b	0.7	4.2
			SMP Level	1abc	0.7	4.6
			RMP Level	2abc	0.6	4.4
	Right	20.5	SenseMP	1c	0.7	4.8
			ReviewMP	1c	0.7	4.8
			Level	1abc	0.6	4.4
7	Left	16.6	SenseMP	2a	3.0	4.0
			ReviewMP	2c	1.6	4.6
			Level	2abc	2.1	2.6
	Right	14.6	SenseMP	2c	2.2	4.0
			ReviewMP	2b	1.2	4.8
			Level	2abc	1.5	2.0
8	Left	16.6	SenseMP	2c	2.2	4.4
			ReviewMP	2a	1.1	3.2
			Level	2abc	1.5	1.6
	Right	16.6	SenseMP	2a	5.2	3.0
			ReviewMP	3	1.1	3.8
			SMP Level	2abc	3.3	2.6
9	Left	20.5	SenseMP	2b	1.9	4.4
			ReviewMP	2abc	1.1	3.2
	Right	18.6	SenseMP	2c	1.3	4.6
			ReviewMP	2a	0.9	4.4
			Level	2abc	0.9	3.2

10	Left	13.7	SenseMP	2c	2.0	4.0
			ReviewMP	2abc	1.4	4.0
	Right	13.7	SenseMP	1c	1.6	4.6
			ReviewMP	2abc	1.2	4.6
			SMP Level	1abc	1.3	4.4

Freq: frequency, Amp: amplitude, TW: therapeutic window, Level: summed segmented contacts of the level when SenseMP and ReviewMP selected a contact on the same level, RMP Level: level of ReviewMP selected segmented contact when SenseMP and ReviewMP levels differed, SMP Level: level of SenseMP selected segmented contact when SenseMP and ReviewMP levels differed; When ReviewMP selected a full level and SenseMP and ReviewMP resulted on the equivalent level, only 2 contact configurations are reported (to remove redundancy between equivalent ReviewMP, SMP Level, and RMP Level parameters).

Efficiency differences between SenseMP and ReviewMP

To represent utilization of SenseMP in clinical practice, the duration to complete ReviewMP of

the SenseMP identified contact(s) with maximal peak beta power (ReviewMP[1]) was compared

to the duration of ReviewMP. Across subjects, the duration of SenseMP (single recording for

both monopolar configurations; levels and segments) combined with the ReviewMP of the

SenseMP identified contact was 17.1 ± 4.2 minutes. The total average duration for the

ReviewMP was 129.9 ± 24.9 minutes across all patients. These durations were significantly

different between conditions ($t(19)$ = 22.53, p = 3.59e-15; Figure 2A). The duration to complete

ReviewMP was of greater variability compared with sensing across all subjects, as evident in the

differences in standard deviation.

Motor outcome measures between SenseMP and ReviewMP

Combined MDS-UPDRS sub-scores for rigidity, bradykinesia, and tremor were not significantly

different between conditions ($t(18)$ = -0.10, p = 0.91). A complementary analysis was conducted

on the percent difference values derived for each condition compared to baseline using a

paired t-test ($t(18)$ = 0.185, p = 0.85; mean percent difference SenseMP = 60.5 ± 15.3 and

ReviewMP = 60.1 ± 13.5). In addition, an ANOVA for condition by sub-score (Figure 2B)

demonstrated a non-significant omnibus for condition ($F(1,108)$ = 0.002, p = 0.96) and condition

by sub-scale interaction ($F(2,108)$ = 0.12, p = 0.887). Post-hoc Tukey HSD comparisons for the

sub-scores demonstrated no differences between conditions (rigidity: $t(108)$ = -0.38, p = 0.99

(Figure 2C); bradykinesia: $t(108) = 0.308$, $p = 1$ (Figure 2D); tremor: $t(108) = 1.43e-15$, $p = 1$

(Figure 2E)).

Figure 2: *A*) Total time (minutes) to complete ReviewMP (black circles) and sensing of monopolar and bipolar recording configurations to derive the contact with maximum beta power (SenseMP) in addition to ReviewMP of the identified contact (ReviewMP[1]) (gold circles). ReviewMP took on average seven times longer to perform than sensing. There was greater variability in duration to complete ReviewMP compared with SenseMP + ReviewMP[1]. Means are expressed for both conditions with horizontal lines. P-value is indicative of significant difference. *B*) Comparison of optimal contacts defined by ReviewMP (black circles) and SenseMP (gold circles), assessed in a double-blind comparison, resulted in equivalent motor symptom outcomes as measured by MDS-UPDRS Part III, in which each point represents a sum of the unilateral hemi-body sub scores of *C-E*. *C*) Unilateral hemi-body sub scores for rigidity (MDS-UPDRS items 3.3). *D*) Unilateral hemi-body sub scores for bradykinesia (MDS-UPDRS items 3.4, 3.5, 3.6, 3.7, and 3.8). *E*) Unilateral hemi-body sub scores for tremor (MDS-UPDRS items 3.15, 3.16, 3.17, and 3.18). Larger circles indicate the average for the sub scores as a function of the condition.

Comparison of therapeutic window between SenseMP and ReviewMP

ANOVA comparison of the SenseMP Level, SenseMP Segment and ReviewMP indicated a significant difference in the TW ($F(2,56)=9.48$, $p < 0.001$). Post-hoc Tukey's HSD tests indicated that TW for ReviewMP (3.98 ± 0.76mA) and SenseMP of the segment (3.83 ± 0.87mA) were not significantly different ($t(56) = 0.52$, $p = 0.86$). However, both SenseMP of the segment and ReviewMP had greater TW than SenseMP of the level (2.85 ± 1.01mA; $t(56) = -3.4$, $p = 0.003$ and $t(56) = 4.01$, $p < 0.001$, respectively; Table 2). In three of the twenty hemispheres (2L, 8L, 9L), the contact selected by ReviewMP differed from the contact with the greatest TW, due to the selected contact having a lower stimulation amplitude to eliminate upper extremity rigidity. In one hemisphere (9R), the contact selected by ReviewMP was selected because it induced dyskinesias at higher stimulation amplitudes.

Comparison of SenseMP and ReviewMP in contact selection and therapeutic response

Qualitative assessment and comparison of contact level localization between SenseMP and ReviewMP demonstrated that for 15/20 hemispheres, the condition-derived optimal contact configurations were on the same level (Figure 3A). In 5/20 hemispheres, the SenseMP and ReviewMP selected segments were identical. In 7/20 hemispheres, ReviewMP selected a level, while SenseMP only selected a level in 1/20 hemispheres, . Quantitative analysis demonstrated no difference between SenseMP and ReviewMP for level localization of optimal contact configurations ($\chi^2(3) = 5.33$, $p = 0.37$). For the 5 hemispheres determined to be on different levels between conditions, the ReviewMP derived contact was superior to the SenseMP derived contact level in 4/5 cases. Orientation analysis was conducted on the 8 hemispheres with ReviewMP selecting segmented contacts that could be directly compared to the SenseMP segments. Qualitative assessment (Figure 3B) demonstrated an apparent lateral bias for segments selected by ReviewMP and, conversely, a medial bias for segments selected by SenseMP. However, quantitatively this difference was non-significant ($\chi^2(7) = 9.3$, $p = 0.15$).

328   Visual inspection demonstrated more easily differentiated beta peaks with SenseMP compared

329   with SenseBP for level (Figure 4A & 4B), which was even more apparent for segments (Figure 4C

330   & 4D). Statistical analysis of the observed distribution for SenseBP level configuration based on

331   maximum beta power (i.e., 0-level between contacts, 1-l

Figure 3: *A*) In 15/20 hemispheres, the SenseMP and ReviewMP contacts were localized within the same level, and for 5/20 hemispheres the SenseMP and ReviewMP contacts were localized one level apart. *B*) The distribution of segment orientations for SenseMP contacts exhibited a greater proportion in the medial region of STN, whereas the ReviewMP segment contacts appeared to have a greater proportion in the lateral region of STN. A: anterior, AL: anterior-lateral, AM: anterior-medial, L: lateral, M: medial, P: posterior, PL: posterior-lateral, PM: posterior-medial.

evel between contacts, and 2-level between contacts) demonstrated a significant difference in

relative count (with respect to the expectation of equal representation; $\chi^2(2) = 6.1$, p = 0.047; 0-

level = 7, 1-level = 11 and 2-level = 2) (Figure 4E & 4F). We next evaluated the alignment of the

SenseMP maximum beta level with the SenseBP configuration, with respect to whether

SenseMP level was aligned with the superior (top), inferior (bottom), or middle contacts of the

SenseBP configuration. The analysis of the observed distribution of SenseMP for level

Figure 4: Comparison of SenseMP and SenseBP configurations. *A-D*) A single representative set of LFP recordings from a single subject's hemisphere. Power spectral density plots depict differences in power within the beta frequency range. *A*) SenseBP for contact levels. *B*) SenseMP for contact levels. *C*) SenseBP for segments. *D*) SenseMP for segments. *E*) Schematic representation and summary of contact configurations derived from the SenseBP levels with the highest beta power paired with their corresponding SenseMP level with the highest beta power. *F*) Number of hemispheres exhibiting the three possible bipolar configurations: No Level (0-level between contacts), One Level (1-level between contacts), and Two Levels (2-level between contacts). *G*) Number of hemispheres exhibiting the three possible corresponding positions of SenseMP level contacts with respect to the SenseBP configuration.

identified maximum beta SenseBP contact did not result in a significant difference in relative

count (with respect to the expectation of equal representation; $\chi^2(2)$ = 4.9, p = 0.086; Superior =

11, Inferior = 6, and Middle = 3). Notably, for 85% of the comparisons, the maximum SenseMP

level contact was one of the SenseBP contacts (17/20), with the remaining three SenseMP level

contacts identified as the 'middle' contact of a 1-level or 2-level between contact SenseBP

configuration (Figure 4E & 4G).

In an analysis of the three subject hemispheres identifying the SenseMP contact as between the

two SenseBP contacts, the difference in peak beta power between the maximum SenseMP

contact and a subsequent contact of SenseBP was minimal. For Subject 2L (i.e., Subject 2, Left

STN), the peak beta power of the SenseMP was 2.7μVp, and the second-best contact, as

identified by beta, had a peak beta power of 2.2μVp. Subject 6, for both left and right

hemispheres, had minimal difference (<0.1μVp difference), as assessed by SenseMP beta peaks

between two contacts, with the second highest peak contact being identified by SenseBP.

Segmental analysis indicated that the contacts of SenseBP consistently identified one of the

SenseMP contacts (20/20; $\chi^2(1)$ = 20, p = 7.74e-6). In 12/20 cases, the SenseMP segment was

the superior contact; in 6/20 cases, it was the inferior contact of the two SenseBP contacts

($\chi^2(1)$ = 2, p = 0.15). Notably, only 2/20 cases of the bipolar configuration were on the same

level (e.g. 2a-2b) with all other 18/20 cases being on adjacent levels but on the same vertical

segment orientation (e.g. 1a-2a; $\chi^2(1)$ = 12.8, p = 3.46e-4). In no case was there a deviation of

SenseBP being on different levels and of different segmental orientations (e.g. 1a-2c).

Furthermore, in no cases was the SenseMP segment between SenseBP contacts within the

same level.

Discussion

In this study, we compared the efficiency and efficacy of using maximum beta power recorded

during SenseMP versus traditional ReviewMP to select the optimal therapeutic DBS contact in

PD subjects undergoing initial programming with STN-DBS. The key findings from this study

were 1) no significant difference in clinical outcome, as measured by MDS-UPDRS Part III (Items

3.4, 3.5, 3.6, 3.7, 3.8, 3.15, 3.16, 3.17, and 3.18) between SenseMP and ReviewMP, 2) non-

inferiority at time of initial programming of SenseMP for determination of initial DBS contact

selection, 3) an 85% shorter duration in obtaining contact selection using SenseMP as

compared to ReviewMP, 4) 75% agreement for contact level selection between SenseMP and

ReviewMP, 5) greater qualitative differentiation between contacts based on beta power

magnitude for SenseMP than SenseBP (commercially available sensing configuration), 6) 85%

agreement between SenseMP identified contact levels and one of the SenseBP contact levels.

Results from this study are well positioned within growing literature on the potential utility of

commercially accessible LFP montages in DBS programming based upon beta power[18-20].

Recently, in a randomized, blinded, three-condition trial in STN-DBS treated PD subjects, the

clinical efficacy and time efficiency of ReviewMP were compared to both imaging-guided and

SenseBP-guided programming[17], finding no difference in clinical efficacy but significantly

improved efficiency for both imaging-guided and SenseBP-guided compared to ReviewMP-

guided programming. In our study, the time duration to complete the SenseMP condition

included recordings for both SenseMP and SenseBP, repeated three times. Clinical efficiency is

also impacted by the capacity to differentiate between contacts based on maximum beta

power. In this regard, SenseMP qualitatively permits more clearly resolved differences between

contacts based on beta power, when compared to SenseBP, and does not require the use of

complex algorithms or real-time problem solving to determine the optimal contact within the

bipolar pair to program[18]. As exemplified by Binder et al., (2023)[17], there was ambiguity in

which contact to stimulate within SenseBP-identified pairs, resulting in the group electing to

evenly distribute stimulation between the two segmented contacts in the pair. The regional

bias appreciated in our study may corroborate recent reports validating that bradykinesia

suppression appears to result from more medial modulation of the STN, and beta power is

known to correlate more prominently with bradykinesia[24]. There is also evidence that rigidity

suppression may have a superior bias in the STN, which may partially explain our observation

that in 5/20 hemispheres, the ReviewMP optimal contact was more superior to the contact

selected by SenseMP[25]. Finally, the TW of SenseMP of the level, but not of the segment, was

significantly less compared with ReviewMP. In five conditions, the SenseMP level was more

ventral to ReviewMP contact(s) and had a lower threshold to induce dyskinesias (N=2),

paresthesias (N=2) and hyphophonia (N=1).

In this first use of SenseMP with fully implanted systems, we focused on identifying the contact

with maximum beta power, but other neurophysiological markers other than beta may be of

great value (e.g. alpha, gamma) and should also be studied, especially considering the

heterogeneity of PD symptoms. SenseMP is a potentially powerful tool in DBS programming;

however, it currently cannot be employed in patients with 1) unilateral implants, 2) bilateral

lead implants driven by separate neurostimulators, or 3) implanted systems with high

impedance. Consequently, the use of SenseBP will be of value in these scenarios and as our

study suggests, one of the contact pairs having the greatest peak beta may be selected for

programming. Finally, SenseMP resulted in a predominant bias to select segmented contacts

(19/20) due to the greater surface area of the contact as well as the surgical targeting strategy

in the current study.

There are several limitations to our study, though many are inherent and acknowledged in

clinical practice. For example, ReviewMP is highly operator-dependent and potentially prone to

bias, as evident in our study. In addition, a selected contact may have greater improvement of

motor symptoms at lower stimulation but also have a lower amplitude threshold to induce

adverse effects compared to an adjacent contact. Such a contact may have a lower TW but be

clinically more ideal since greater motor response is achieved with less stimulation[26].

Furthermore, although the MDS-UPDRS is an established and validated scale, subtle differences

in therapeutic response across tested contacts may not be adequately represented or

appreciated by the examiner. Another limitation of the study is that evaluations were only

performed in the acute setting and the long-term effects of programming by SenseMP are

unknown.

This study demonstrates that SenseMP STN DBS programming may be a time-efficient and

clinically effective tool in DBS programming for PD patients. It is likely that SenseMP will allow

practitioners to focus on testing contacts with ReviewMP that have the greatest therapeutic

benefit, thus better utilizing clinical time. It will be important to evaluate potential future

research endeavors and clinical application of SenseMP as this technology becomes more

widely available.

Figure Legends

Figure 1: Workflow diagram of the study design

Figure 2: *A*) Total time (minutes) to complete ReviewMP (black circles) and sensing of

monopolar and bipolar recording configurations to derive the contact with maximum beta

power (SenseMP) in addition to ReviewMP of the identified contact (ReviewMP[1]) (gold circles).

ReviewMP took on average seven times longer to perform than sensing. There was greater

variability in duration to complete ReviewMP compared with SenseMP + ReviewMP[1]. Means

are expressed for both conditions with horizontal lines. P-value is indicative of significant

difference. *B*) Comparison of optimal contacts defined by ReviewMP (black circles) and

SenseMP (gold circles), assessed in a double-blind comparison, resulted in equivalent motor

symptom outcomes as measured by MDS-UPDRS Part III, in which each point represents a sum

of the unilateral hemi-body sub scores of *C-E*. *C*) Unilateral hemi-body sub scores for rigidity

(MDS-UPDRS items 3.3). *D*) Unilateral hemi-body sub scores for bradykinesia (MDS-UPDRS

items 3.4, 3.5, 3.6, 3.7, and 3.8). *E*) Unilateral hemi-body sub scores for tremor (MDS-UPDRS

items 3.15, 3.16, 3.17, and 3.18). Larger circles indicate the average for the sub scores as a

function of the condition.

Figure 3: *A*) In 15/20 hemispheres, the SenseMP and ReviewMP contacts were localized within

the same level, and for 5/20 hemispheres the SenseMP and ReviewMP contacts were localized

one level apart. *B*) The distribution of segment orientations for SenseMP contacts exhibited a

greater proportion in the medial region of STN, whereas the ReviewMP segment contacts

appeared to have a greater proportion in the lateral region of STN. A: anterior, AL: anterior-

lateral, AM: anterior-medial, L: lateral, M: medial, P: posterior, PL: posterior-lateral, PM:

posterior-medial.

Figure 4: Comparison of SenseMP and SenseBP configurations. *A-D*) A single representative set

of LFP recordings from a single subject's hemisphere. Power spectral density plots depict

differences in power within the beta frequency range. *A*) SenseBP for contact levels. *B*)

SenseMP for contact levels. *C*) SenseBP for segments. *D*) SenseMP for segments. *E*) Schematic

representation and summary of contact configurations derived from the SenseBP levels with

the highest beta power paired with their corresponding SenseMP level with the highest beta

power. *F*) Number of hemispheres exhibiting the three possible bipolar configurations: No Level

(0-level between contacts), One Level (1-level between contacts), and Two Levels (2-level

between contacts). *G*) Number of hemispheres exhibiting the three possible corresponding

positions of SenseMP level contacts with respect to the SenseBP configuration.

Table 1: Subject Demographics

Table 2: SenseMP and ReviewMP of lead segment and level

ACKNOWLEDGEMENTS: We are grateful for the patients who participated in this study.

Funding for this investigator-initiated study was provided by Medtronic.

COMPETING INTERESTS: JAT declares the following competing financial interest: received

research funding from Medtronic and the following non-financial competing interest: used

investigational system provided by Medtronic, DSK received research funding from Medtronic

and the following non-financial competing interest: used investigational system provided by

Medtronic. AHB, CZ, MC, RSR declare both financial and non-financial competing interests as

employees of Medtronic. SO has received fellowship support funding from Medtronic, Boston

Scientific and Abbott. EMR and AJB declare no competing financial or non-financial interests.

AUTHOR CONTRIBUTIONS: EMR: collected data, drafted original version, revised final draft;

DRK: revised final draft; SO: collected data; MC: contributed analysis tools, revised paper; CZ:

contributed analysis tools, revised paper; AHB: contributed analysis tools, revised paper; RR:

contributed analysis tools, revised paper; AJB: collected data; DSK: conceived of study, collected

data, drafted original version, revised final draft; JAT: conceived of study, collected data,

developed analysis tools, drafted original version, revised final draft.

<u>References</u>

1. Benabid AL, Benazzouz A, Hoffmann D, Limousin P, Krack P, Pollak P. Long-term electrical
inhibition of deep brain targets in movement disorders. *Mov Disord*. 1998;13 Suppl 3:119-25.
doi:10.1002/mds.870131321
2. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the
subthalamic nucleus in advanced Parkinson's disease. *N Engl J Med*. Nov 13 2003;349(20):1925-34.
doi:10.1056/NEJMoa035275
3. Kühn AA, Kempf F, Brücke C, et al. High-frequency stimulation of the subthalamic nucleus
suppresses oscillatory beta activity in patients with Parkinson's disease in parallel with improvement in
motor performance. *J Neurosci*. Jun 11 2008;28(24):6165-73. doi:10.1523/jneurosci.0282-08.2008
4. Kühn AA, Kupsch A, Schneider GH, Brown P. Reduction in subthalamic 8-35 Hz oscillatory activity
correlates with clinical improvement in Parkinson's disease. *Eur J Neurosci*. Apr 2006;23(7):1956-60.
doi:10.1111/j.1460-9568.2006.04717.x
5. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced
Parkinson's disease. *N Engl J Med*. Oct 15 1998;339(16):1105-11. doi:10.1056/nejm199810153391603
6. Dembek TA, Roediger J, Horn A, et al. Probabilistic sweet spots predict motor outcome for deep
brain stimulation in Parkinson disease. *Ann Neurol*. Oct 2019;86(4):527-538. doi:10.1002/ana.25567
7. Horn A, Neumann WJ, Degen K, Schneider GH, Kühn AA. Toward an electrophysiological "sweet
spot" for deep brain stimulation in the subthalamic nucleus. *Hum Brain Mapp*. Jul 2017;38(7):3377-
3390. doi:10.1002/hbm.23594
8. Ince NF, Gupte A, Wichmann T, et al. Selection of optimal programming contacts based on local
field potential recordings from subthalamic nucleus in patients with Parkinson's disease. *Neurosurgery*.
Aug 2010;67(2):390-7. doi:10.1227/01.Neu.0000372091.64824.63
9. Thompson JA, Oukal S, Bergman H, et al. Semi-automated application for estimating
subthalamic nucleus boundaries and optimal target selection for deep brain stimulation implantation
surgery. *J Neurosurg*. May 18 2018;130(4):1224-1233. doi:10.3171/2017.12.Jns171964
10. Zaidel A, Spivak A, Grieb B, Bergman H, Israel Z. Subthalamic span of beta oscillations predicts
deep brain stimulation efficacy for patients with Parkinson's disease. *Brain*. Jul 2010;133(Pt 7):2007-21.
doi:10.1093/brain/awq144

11.   Butson CR, McIntyre CC. Current steering to control the volume of tissue activated during deep
brain stimulation. *Brain Stimul*. Jan 2008;1(1):7-15. doi:10.1016/j.brs.2007.08.004
12.   Cagnan H, Denison T, McIntyre C, Brown P. Emerging technologies for improved deep brain
stimulation. *Nat Biotechnol*. Sep 2019;37(9):1024-1033. doi:10.1038/s41587-019-0244-6
13.   Connolly AT, Vetter RJ, Hetke JF, et al. A Novel Lead Design for Modulation and Sensing of Deep
Brain Structures. *IEEE Transactions on Biomedical Engineering*. 2016;63(1):148-157.
doi:10.1109/TBME.2015.2492921
14.   Dembek TA, Reker P, Visser-Vandewalle V, et al. Directional DBS increases side-effect
thresholds-A prospective, double-blind trial. *Mov Disord*. Oct 2017;32(10):1380-1388.
doi:10.1002/mds.27093
15.   Timmermann L, Jain R, Chen L, et al. Multiple-source current steering in subthalamic nucleus
deep brain stimulation for Parkinson's disease (the VANTAGE study): a non-randomised, prospective,
multicentre, open-label study. *Lancet Neurol*. Jul 2015;14(7):693-701. doi:10.1016/s1474-
4422(15)00087-3
16.   Tinkhauser G, Pogosyan A, Debove I, et al. Directional local field potentials: A tool to optimize
deep brain stimulation. *Mov Disord*. Jan 2018;33(1):159-164. doi:10.1002/mds.27215
17.   Binder T, Lange F, Pozzi N, et al. Feasibility of local field potential-guided programming for deep
brain stimulation in Parkinson's disease: A comparison with clinical and neuro-imaging guided
approaches in a randomized, controlled pilot trial. *Brain Stimul*. Sep-Oct 2023;16(5):1243-1251.
doi:10.1016/j.brs.2023.08.017
18.   Lewis S, Radcliffe E, Ojemann S, et al. Pilot Study to Investigate the Use of In-Clinic Sensing to
Identify Optimal Stimulation Parameters for Deep Brain Stimulation Therapy in Parkinson's Disease.
Neuromodulation: Technology at the Neural Interface. 2024/04/01/ 2024;27(3):509-519.
doi:https://doi.org/10.1016/j.neurom.2023.01.006
19.   Baker S, Radcliffe, E, Baumgarter, A, Kramer, D, Ojemann, Kern, D, Thompson, JA. Towards an
objective, standardized beta frequency peak detection algorithm to inform adaptive deep brain
stimulation programming in Parkinson's disease. *PREPRINT (Version 1) Research Square*
2024;doi:https://doi.org/10.21203/rs.3.rs-3994762/v1
20.   Strelow JN, Dembek TA, Baldermann JC, et al. Low beta-band suppression as a tool for DBS
contact selection for akinetic-rigid symptoms in Parkinson's disease. *Parkinsonism Relat Disord*. Jul
2023;112:105478. doi:10.1016/j.parkreldis.2023.105478
21.   Swinnen B, Buijink AW, Piña-Fuentes D, de Bie RMA, Beudel M. Diving into the subcortex: The
potential of chronic subcortical sensing for unravelling basal ganglia function and optimization of deep
brain stimulation. *Neuroimage*. Jul 1 2022;254:119147. doi:10.1016/j.neuroimage.2022.119147
22.   Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of
the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.
Mov Disord. Jan 2007;22(1):41-7. doi:10.1002/mds.21198
23.   Abosch A, Timmermann L, Bartley S, et al. An international survey of deep brain stimulation
procedural steps. *Stereotact Funct Neurosurg*. 2013;91(1):1-11. doi:10.1159/000343207
24.   Rodriguez-Rojas R, Pineda-Pardo JA, Mañez-Miro J, et al. Functional Topography of the Human
Subthalamic Nucleus: Relevance for Subthalamotomy in Parkinson's Disease. *Mov Disord*. Feb
2022;37(2):279-290. doi:10.1002/mds.28862
25.   Akram H, Sotiropoulos SN, Jbabdi S, et al. Subthalamic deep brain stimulation sweet spots and
hyperdirect cortical connectivity in Parkinson's disease. *Neuroimage*. Sep 2017;158:332-345.
doi:10.1016/j.neuroimage.2017.07.012
26.   Busch JL, Kaplan J, Bahners BH, et al. Local Field Potentials Predict Motor Performance in Deep
Brain Stimulation for Parkinson's Disease. *Mov Disord*. Dec 2023;38(12):2185-2196.
doi:10.1002/mds.29626

Conflict of interest: Robert Raike, Abbey Becker, and Michelle Case are Medtronic employees.

In this study, they provided technical support and assistance in imaging analysis. They were not

involved in the conduct of patient care and did not influence the interpretation of the results.

Drew Kern and John Thompson received funding from Medtronic to support this study. Study

concept, execution, analysis, and interpretation were developed independently by Drew Kern

and John A Thompson.

Funding: Medtronic Collaboration Grant

583